This seems to be interesting, although not so related to TDI...
Begin forwarded message:
Date: Sat, 22 Jan 2005 18:23:25 +0100 (CET)
From: Andreas Tille <>
To: Debian Med Project List <>
Subject: Open Source Stem Cell R&D (fwd)
Hi,
I did not really found a download or a license but if there is any
interest
someone might do a more detailed research on the home page
http://usbiodefense.com/news_012105.php
which seams responsible for the message on LinuxMedNews:
http://linuxmednews.com/linuxmednews/1106324091/index_html
U.S. BioDefense to Launch Open Source Platform for Rapid Stem Cell
Research and
Development. Read on for the complete announcement.
City of Industry, CA January 21, 2005 - U.S. BioDefense, Inc. (OTCBB:
UBDF)
announced today that it is developing an Open Source Stem Cell Research
Platform to leverage the distributed power of open source development.
The Open
Source Stem Cell Research Platform will allow researchers at
Universities,
Government Agencies, and Fortune 500 companies to read, distribute,
modify and
contribute to stem cell and biotechnology research in an efficient and
streamlined method. The platform which can be used as an Intranet or
online
will provide access to bioinformatic tools and serve as a robust utility
for
the rapid evolution of Stem Cell technology research, development, and
commercialization.
U.S. BioDefense CEO David Chin stated, We intend to quickly scale up
revenues
by focusing on selling Open Source collaborative technology research and
transfer tools as well as commercializing leading edge technology. The
proliferation of open source development to industries beyond software
has
prompted U.S. BioDefense to aggressively lead the drive in implementing
the
philosophy and benefits to the emerging stem cell industry. We are
positioning
ourselves at the nucleus of Stem Cell research and development tools in
order
to leverage the potential of California's $3 Billion Stem Cell Research
Fund
and our Department of Defense SBIR Grant response related to Embryonic
Stem
Cell technology for Bioengineered skin commercialization.
U.S. BioDefense is aggressively pursuing its technology transfer
initiative by
incorporating the distributed power of open source development in
individual
biotechnology fields related to biodefense research beginning with its
Stem
Cell commercialization initiative. The Open Source Stem Cell Research
Platform
being developed by U.S. BioDefense is an adaptation of the monumental
open
source movement in software development that has also been embraced by
large
technology companies like IBM (NYSE: IBM), Novell and Sun Microsystems
(Nasdaq:
SUNW).
According to Wired Magazine recently the idea of open source
biotechnology has
been gaining momentum with the introduction of BIOS, the Biological
Innovation
for Open Society (www.bios.net), a non profit with the support of The
Rockefeller Foundation encompassing the creative use of living systems
and
their environment, and with the implementation of open source principles
and
development methods in the field of bioinformatics. According to BIOS
web site
the organization will create a mechanism BioForge by which like-minded
individuals and agencies can collaborate with optimum effectiveness to
solve
problems and create technologies under an open-access regime. The goal
of
BioForge is to forge a dynamic protected commons of enabling
technologies that
will be available to the worldwide inventive community for use in
improvement
and new innovations. The VA Software SourceForge.net Open Source network
provides a scalable solution for empowering development teams across the
diverse worldwide Open Source community. Today, SourceForge.net is the
world's
largest Open Source software development web site, hosting more than
90,000
projects and over 950,000 registered users. OSTG receives more than 230
million
page views and over 16 million unique visitors every single month.
About U.S. BioDefense, Inc.
U.S. BioDefense is a Department of Defense central contractor that
researches,
develops, and commercializes leading-edge biotechnology. U.S. BioDefense
recently announced that it had filed its Small Business Innovation
Research
(SBIR) Grant proposal Number C051-117-0060 with the Department of
Defense
Chemical Biological Defense Agency in response to SBIR (dodsbir.net)
Topic
number CBD05-117 'Stem Cell Technology And Autologous Bioengineered Skin
For
The Treatment of Cutaneous Vesicant Injury'. U.S. BioDefense recently
sponsored
the Project T2 Technology Transfer Conference, the nation's leading
showcase of
new university technologies, being hosted at the Wilshire Grand Hotel in
Los
Angeles, CA. Other sponsors (http://www.projectt2.org/sponsors.htm)
include
Southern California Edison, Latham & Watkins, Morrison & Foerster,
PricewaterhouseCoopers, Canadian Consulate General, and Genzyme (NYSE:
GENZ).
U.S. BioDefense, Inc. recently entered into a Commercial Evaluation
License
Agreement with the National Institutes of Health (NIH). The
biotechnology is
related to a method for universal inactivation of viruses, parasites and
tumor
cells. These inactivated agents can be used as vaccines against the
diseases
caused by such viruses, parasites and tumor cells. Hence, the
immunogenic of
the agent as a whole is maintained and can be safely used for
vaccination
without the threat of infection. U.S. BioDefense, Inc. intends to
conduct
laboratory experiments under this Agreement to evaluate the suitability
for
commercial development. Furthermore, U.S. BioDefense, Inc. has agreed to
provide the facilities, personnel, and expertise to evaluate the
commercial
applications. NIH's bioterrorism budgets have jumped from $53 million in
2001
to $1.7 Billion in 2005.
Safe Harbor Statement Forward-Looking Statements Included in this
release are
certain forward-looking'' statements, involving risks and
uncertainties, which
are covered by the safe harbor provisions of the Private Securities
Litigation
Reform Act of 1995, including statements regarding the Company's
financial
performance. Such statements are based on management's current
expectations and
are subject to certain factors, risks and uncertainties that may cause
actual
results, events and performance to differ materially from those referred
to or
implied by such statements. In addition, actual future results may
differ
materially from those anticipated, depending on a variety of factors,
including
continued maintenance of favorable license arrangements, success of
market
research identifying new product opportunities, successful introduction
of new
products, continued product innovation, the success of enhancements to
the
Company's brand image, sales and earnings growth, ability to attract and
retain
key personnel, and general economic conditions affecting consumer
spending,
including uncertainties relating to global political conditions, such as
terrorism. Information with respect to important factors that should be
considered is contained in the Company's Annual Report on Form 10-K as
filed
with the Securities and Exchange Commission. Readers are cautioned not
to place
undue reliance on these forward-looking statements, which speak only as
of the
date hereof. The Company does not intend to update any of the
forward-looking
statements after the date of this release to conform these statements to
actual
results or to changes in its expectations, except as may be required by
law.
CONTACT:
U.S. BioDefense, Inc.
David Chin, 626-961-0562
< | Washington Monthly: The Best Care Anywhere >
--
To UNSUBSCRIBE, email to
with a subject of "unsubscribe". Trouble? Contact
--
Luca Brivio
Web: http://icebrook.altervista.org
Jabber:
________________________________________________________________________
"Homo sum: humani nil a me alienum puto" (P. Terentius Afer)
________________________________________________________________________
Attachment:
pgpUMJP1kseoy.pgp
Description: PGP signature